Neurological Sciences

, Volume 32, Issue 4, pp 609–613 | Cite as

Memantine attenuates the impairment of spatial learning and memory of pentylenetetrazol-kindled rats

  • Li-Jing Jia
  • Wei-Ping Wang
  • Zhou-Ping Li
  • Jun-Li Zhen
  • Li-Wei An
  • Rui-Sheng Duan
Original Article

Abstract

Cognitive disorders after epilepsy can have a great impact on the quality of life of epileptic patients, though it has not drawn much attention. Even after identified, it is often undertreated or has gone untreated. Memantine has been approved to treat moderate to severe Alzheimer disease (AD), which is characterized by cognitive impairment. In present study, we determined the effects of memantine on PTZ-kindled rats, which can mimic the postseizure dysfunction that resembles symptoms observed in human epilepsy. We found that memantine can ameliorate the spatial learning and memory of epileptic rats. But contrary to previous claims that memantine can improve cognition in AD patients, without serious side effects on normal learning and memory abilities, we found that rats treated only with memantine exhibited the impaired spatial learning and memory ability. We conclude that memantine can improve cognition related to an excitotoxicity-induced pathologic state, but the potential side effects of memantine on the physiological processes should be considered.

Keywords

Epilepsy Cognition Spatial learning and memory Kindling Memantine Pentylenetetrazol 

References

  1. 1.
    Soria C, Callu D, Viguier D, SEl Sabbagh, Bulteau C, Laroussinie F, Dellatolas G (2008) Parental report of cognitive difficulties quality of life and rehabilitation in children with epilepsy or treated for brain tumour. Dev Neurorehabil 11:268–275PubMedCrossRefGoogle Scholar
  2. 2.
    Aldenkamp AP, Bodde N (2005) Behaviour, cognition and epilepsy. Acta Neurol Scand Suppl 182:19–25CrossRefGoogle Scholar
  3. 3.
    Elger CE, Helmstaedter C, Kurthen M (2004) Chronic epilepsy and cognition. Lancet Neurol 3:663–672PubMedCrossRefGoogle Scholar
  4. 4.
    Motamedi G, Meador K (2003) Epilepsy and cognition. Epilepsy Behav Suppl 2:S25–S38CrossRefGoogle Scholar
  5. 5.
    Kohr G (2007) NMDA receptor antagonists:tools in neuroscience with promise for treating CNS pathologies. J Physiol 581:1–2PubMedCrossRefGoogle Scholar
  6. 6.
    Ott BR, Blake LM, Kagan E, Resnick M (2007) Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease. J Neurol 254:351–358PubMedCrossRefGoogle Scholar
  7. 7.
    Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S (2006) Memantine treatment in mild to moderate Alzheimer disease: randomized, a 24-week controlled trial. Am J Geriatr Psychiatry 14:704–715PubMedCrossRefGoogle Scholar
  8. 8.
    Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22:209–221PubMedCrossRefGoogle Scholar
  9. 9.
    Schmitt FA, van Dyck CH, Wichems CH, Olin JT (2006) Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord 20:255–262PubMedCrossRefGoogle Scholar
  10. 10.
    Mortazavi F, Ericson M, Story D, Hulce VD, Dunbar GL (2005) Spatial learning deficits and emotional impairments in pentylenetetrazole-kindled rats. Epilepsy Behav 7:629–638PubMedCrossRefGoogle Scholar
  11. 11.
    Wang P, Wang WP, Zhang S, Wang HX, Lou Y, Fan YH (2008) Impaired spatial learning related with decreased expression of calcium/calmodulin-dependent protein kinase IIαand cAMP-response element binding protein in the pentylenetetrazol-kindled rats. Brain Res 1238:108–117PubMedCrossRefGoogle Scholar
  12. 12.
    Chen HS, Wang YF, Rayadu PV, Edgecomb P, Neill JC, Segal MM, Lipton SA, Jensen FE (1998) Neuroprotective concentrations of the N-methyl-d-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 86:1121–1132PubMedCrossRefGoogle Scholar
  13. 13.
    Danysz W, Parsons CG (2003) The NMDA receptor antagonist memantine as a symptomological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry 18 Suppl 1: S23–S32Google Scholar
  14. 14.
    Reisberg B, Doody R, Stoffler A (2003) A randomized, placebo-controlled study of memantine, an uncompetitive NMDA antagonist in patients with moderate to sever Alzheimer’s disease. N Engl J Med 348:1333–1341PubMedCrossRefGoogle Scholar
  15. 15.
    Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317–324PubMedCrossRefGoogle Scholar
  16. 16.
    Creeley C, Wozniak DF, Labruyere J, Taylor GT, Olney JW (2006) Low doses of memantine disrupt memory in adult rats. J Neurosci 26:3923–3932PubMedCrossRefGoogle Scholar
  17. 17.
    Racine RJ (1972) Modification of seizure activity by electrical timulation II motor seizure. Electroencephalogr Clin Neurophysiol 32:281–294PubMedCrossRefGoogle Scholar
  18. 18.
    Morris R (1984) Development of a water-maze procedure for studying spatial leaning in the rat. Neurosci Methods 11:47–60CrossRefGoogle Scholar
  19. 19.
    Huang LT, Yang SN, Liou CW, Hung PL, Lai MC, Wang CL, Wang TJ (2002) Pentylenetetrazol-induced recurrent seizures in rat pups: time course on spatial learning and long-term effects. Epilepsia 43:567–573PubMedCrossRefGoogle Scholar
  20. 20.
    Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A (2009) MEM-MD-29 Study Group, A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34:1322–1329PubMedCrossRefGoogle Scholar
  21. 21.
    Wroolie TE, Kenna HA, Williams KE, Powers BN, Holcomb M, Lazzeroni L, Rasgon NL (2009) Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study. Acta Neurol Scand 119:172–179PubMedCrossRefGoogle Scholar
  22. 22.
    Jevtovic-Tedorovic V, Wozniak DW, Benshoff ND, Olney JW (2001) Comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide. Brain Res 895:264–267CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Li-Jing Jia
    • 1
  • Wei-Ping Wang
    • 1
  • Zhou-Ping Li
    • 1
  • Jun-Li Zhen
    • 1
  • Li-Wei An
    • 1
  • Rui-Sheng Duan
    • 1
  1. 1.Department of NeurologyThe Second Hospital of Hebei Medical UniversityShijiazhuangPeople’s Republic of China

Personalised recommendations